Summary Melanoma is a type of cancer that begins in the melanocytes , often in moles or other pigmented tissues . It most commonly affects the skin , as cutaneous melanoma ; however it can also affect other pigmented tissues , such as the eye or intestines , as extracutaneous melanoma . It is the deadliest form of skin cancer and remains one of the most aggressive and treatmentresistant human cancers .
Global prevalence of the disease has risen significantly in the past several decades , primarily due to an increase in exposure to UV light and / or sunlight . This has resulted in an increase in developmental interest with regard to improving disease management , particularly in the advanced metastatic setting .
The emergence over the past decade of novel targeted therapies and therapies that manipulate the immune response has improved treatment options for patients . These new drug classes have been highly commercially successful with blockbuster products that are now well established within the treatment algorithm .
In spite of these developments , there are still significant unmet needs for both cutaneous and extracutaneous melanoma , and the rationale for investment in first-in-class innovation remains strong . First-in-class products account for a considerable proportion of the melanoma pipeline , which is substantially larger than the current market .
Request a sample of this report @ http :// www . orbisresearch . com / contacts / requestsample / 193024 .
Scope Rising global prevalence and unmet need have resulted in an increase in developmental interest - What is the pathophysiology of melanoma ? - How has the emergence of new drug classes in the past decade impacted the treatment algorithm ? - What are the most significant unmet needs within the market ? The melanoma pipeline is large and innovative in comparison with the current market - Which molecule types and molecular targets are most prominent within the pipeline ? - Which first-in-class targets are most promising ? - How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class ? - Do melanoma products attract high deal values ? - Which molecule types and molecular targets dominate the deals landscape ? - Which first-in-class pipeline products have no prior involvement in licensing or codevelopment deals ?
2